Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorArriola, Edurne
dc.contributor.authorGonzalez-Cao, Maria
dc.contributor.authorDe Castro, Javier
dc.contributor.authorBernabé, Reyes
dc.contributor.authorNAVARRO, ALEJANDRO
dc.contributor.authorcobo, manuel
dc.contributor.authorDomine, Manuel
dc.date.accessioned2023-06-08T07:29:28Z
dc.date.available2023-06-08T07:29:28Z
dc.date.issued2022-06
dc.identifier.citationArriola E, González-Cao M, Domine M, De Castro J, Cobo M, Bernabé R, et al. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncol Ther. 2022 Jun;10:167–84.
dc.identifier.issn2366-1089
dc.identifier.urihttps://hdl.handle.net/11351/9684
dc.descriptionChemotherapy; Immunotherapy; Small cell lung carcinoma
dc.description.abstractIntroduction The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. Methods Two independent reviewers extracted relevant data according to PRISMA guidelines and assessed the risk of bias using the Cochrane Collaboration's risk-of-bias tool. Meta-analysis was conducted using random-effects models to calculate an average effect size for overall survival (OS), progression-free survival (PFS), and safety outcomes in the overall populations and clinically relevant subgroups. Results A literature search of PubMed and Embase was performed. Six randomized controlled clinical trials (IMpower133, CHECKMATE-451, CASPIAN, KEYNOTE-604, and phase II and III ipilimumab plus CT trials) with a total of 3757 patients were included. Compared with CT alone, ICIs plus CT showed a favourable effect on OS (hazard ratio [HR] 0.85; 95% confidence intervals [CI] 0.79–0.96) and PFS (HR 0.78; 95% CI 0.72–0.83) but a non-significant increase in the risk of experiencing any adverse event (relative risk, 1.05; 95% CI 0.99–1.11). The estimated HR for OS favoured ICI combinations in all planned subgroups according to age (< 65 years/≥ 65 years), sex (men/women), and ECOG performance status (0/1). Analysis by specific ICI revealed significant improvements in OS only for atezolizumab + CT (HR 1.36; 95% CI 1.09–1.69) and durvalumab + CT (HR 1.35; 95% CI 1.12–1.62) compared with CT alone. Conclusion Combining anti-programmed cell death ligand 1 antibodies with platinum/etoposide is a superior therapeutic approach compared to CT alone for the first-line treatment of patients with ES-SCLC.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesOncology and Therapy;10
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subjectPulmons - Càncer - Immunoteràpia
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleAddition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s40487-021-00182-0
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1007/s40487-021-00182-0
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Arriola E] Medical Oncology Department, Hospital Universitari del Mar-CIBERONC, Barcelona, Spain. [González-Cao M] Medical Oncology Department (IOR), Hospital Dexeus, Barcelona, Spain. [Domine M] Medical Oncology Department, Fundación Jiménez Díaz, Madrid, Spain. [De Castro J] Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain. [Cobo M] Inter-Center Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Bernabé R] Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain. [Navarro A] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35032007
dc.identifier.wos000742566400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record